Why Thermo Fisher’s new Gothenburg lab matters for the next phase of complex drug development
Complex therapies need deeper trial data. Thermo Fisher’s Gothenburg lab shows why bioanalysis is becoming a CRO battleground.
Why bioAffinity’s CyPath Lung growth still leaves investors facing a hard cash question
CyPath Lung is gaining clinical traction. The harder test is whether bioAffinity can scale adoption before cash pressure tightens.
bioAffinity Technologies positions CyPath Lung as a confidence tool rather than a diagnostic replacement
Find out how bioAffinity Technologies’ CyPath Lung could reshape decision making for small lung nodules and what risks remain for adoption.
BD Research Cloud 7.0 introduces Horizon Panel Maker to automate complex experiment setup
BD launches an AI-powered panel design tool for flow cytometry. Find out how it’s reshaping immunology and cancer research automation.